OWC Pharmaceutical Research Corp., a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, reportedrecently that the last healthy volunteer in its first ever safety study of cannabis-based topical ointment, was recently admitted in trial which is being conducted at Sheba Medical Center, Tel Hashomer, Israel.
Mordechai Bignitz, OWC Pharmaceutical CEO commented: “We are extremely pleased with the progress on this trial. Recruiting has now been completed and we expect to complete the trial by the end of December”.
Mr. Bignitz added: “We recently had the opportunity to present our innovative research and pipeline progress to investors and potential business partners at the MJBizCon in Las Vegas. We are evaluating a number of potential avenues to accelerate our development as we strongly believe that our innovative dosage forms, delivery platforms and our clinical research can unlock the potential of cannabis-based treatments and improve patients’quality of life”.